职称：教授，博士

联系方式：南方医科大学药学院

Email: yulezy@smu.edu.cn; yule0423@gmail.com

主要招生方向：药理学、工业药学

工作经历：

2018/12-至今，南方医科大学，教授

2015/09-2017/04，加州大学San Diego分校药理系，访问学者

2011/12-2018/12，南方医科大学，药学院，副教授

2005/10-2011/11，南方医科大学，药学院，讲师

2003/07-2005/09，第一军医大学，中心实验室，助教

学习经历：

2005/10-2009/04，香港中文大学，医学院药理学系，博士

2000/08-2003/06，第一军医大学，药物研究所，硕士

1996/08-2000/06，中国药科大学化学制药专业，学士

承担课程：

《药理学》；《Pharmacology》；《药学英语》

社会工作：

Journal of Clinical Laboratory Analysis副主编

    （https://onlinelibrary.wiley.com/page/journal/10982825/homepage/editorialboard.html）

Exploration of Digestive Diseases编委

    （https://www.explorationpub.com/Journals/edd/Editorial_Board）

科研课题：

1.BAP1突变肿瘤对BET抑制剂易感性的发现及其机制研究，国家自然科学基金面上项目，54万，2020.01-2023.12.

2.利用GNAQ突变与BET抑制剂合成致死作用靶向治疗葡萄膜黑色素瘤，广东省自然科学基金面上项目，10万，2022.01-2024.12

3.BET抑制剂选择性抑制GNAQ突变葡萄膜黑色素瘤的机制研究，眼科学国家重点实验室开放课题，15万，2022.06-2023.12

4.BET蛋白作为抑癌基因BAP1突变恶性肿瘤治疗新靶点的发现，广东省药学会研究基金，25万，2023.01-2024.01

5.基于转录依赖靶向治疗GNAQ/11驱动的葡萄膜黑色素瘤精准个体化治疗探讨，20万，2022.09-2023.09

6.BRD4作为携带BAP1突变葡萄膜黑色素瘤合成致死靶点的发现及机制研究，广东省自然科学基金面上项目，10万，2019.10-2022.09.

7.利用互斥频发突变的合成致死/致病效应靶向治疗葡萄膜黑色素瘤，国家自然科学基金面上项目，25万，2018.01-2019.12.

8.自噬对Bcl-2抑制剂抗消化系统肿瘤作用的影响及其机制研究，广东省教育教育厅，广东省高等学校优秀青年教师培育计划，45万，2014-2016.

9.自噬抑制剂增强顺铂抗耐药性食管癌的作用及其机制研究，国家自然科学基金面上项目，60万，2013.01-2016.12.

10.自噬在人食管癌细胞顺铂耐药的作用, 广州市珠江科技新星，30万，2012.06-2015.06.

11.COX-2抑制剂拮抗铂类抗肿瘤药物活性的研究，广东省教育厅育苗项目，3万，2011.01-2012.12

12.COX-2抑制剂通过非COX-2依赖途径拮抗铂类抗肿瘤药物活性的机理研究，国家自然科学基金青年项目，20万，2011.01-2013.12

主要论著：

Wang HF#, Zhou RH#, Xu FS#, Yang KJ, Zheng LH, Zhao P, Shi GW, Dai LY, Xu CC, Yu L*, Li ZJ*, Wang JH*, Wang JG*. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD). Biomater Res, 2023, 27(1):72.

Zhang GM#, Huang SS#, Ye LX, Liu XL, Shi WH, Ren ZL, Zhou RH, Zhang JJ, Pan JX, Liu SW, Yu L*, Li YL*. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Pharmacol Res, 2022, 184:106464.

Liu XL#, Zhang GM#, Huang SS, Shi WH, Ye LX, Ren ZL, Zhang JJ, Liu SW, Yu L*, Li YL*. PETN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma. Acta Pharmacol Sin, 2022, 43(9):2397-2409.

Xu YY#, Ren ZL#, Liu XL, Zhang GM, Huang SS, Shi WH, Ye LX, Luo X, Liu SW, Li YL*, Yu L*. BAP1 loss augments sensitivity to BET inhibitors in cancer cells. Acta Pharmacol Sin, 2022, 43(7):1803-1815.

Yu L*, Zhou D, Zhang G, Ren Z, Luo X, Liu P, Plouffe SW, Meng Z, Moroishi T, Li Y, Zhang Y, Brown JH, Liu S*, Guang KL*. Co-occurrence of BAP1 and SF3B1 mutations in uveal melanoma induces cellular senescence. Mol Oncol, 2022, 16(3):607-629

Luo X#, Xu Y#, Li Y#, Zhang G,Huang S,Liu X,Ren Z,Liu S,Yu L*. BAP1deletion abrogates growth and metastasis of murine cutaneous melanoma. Melanoma Res, 2021 31(2):119-129.

Lin Q, Que F, Gu C, Zhong D, Zhou D, Kong Y, Yu L*, Liu S*. ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro. Acta Pharmacol Sin, 2017, 38(12):1632-41.

Kong Y, Gu C, Zhong D, Zhao X, Lin Q, Wang K, Xun T, Yu L*, Liu S*. Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx. Eur J Pharma Sci, 2016, 81:137-48.

Yu L, Wu WK, Gu C, Zhong D, Zhao X, Kong Y, Lin Q, Chan MT, Zhou Z, Liu S*. Obtoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells. Oncotarget, 2016, 7(12):14693-707.

Yu L, Gu C, Zhong D, Shi L, Kong Y, Zhou Z, Liu S*. Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. Cancer Lett, 2014, 355(1):34-45.

Zhong D, Gu C, Shi L, Xun T, Li X, Liu S*, Yu L*. Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells. J Cell Biochem, 2014, 115(9):1624-35.

Yu L*, Liu S*. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics. Semin Cancer Biol, 2013, 23:553-60.

Chen M#, Yu L#, Gu C, Zhong D, Wu S, Liu S. Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation. Cancer Lett, 2013, 329(2):189-96.

Yu L, Chen M, Li Z, Wen J, Fu J, Guo D, Jiang Y, Wu S, Cho CH, Liu S*. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. Mol Pharmacol, 2011,79(3):608-17

Yu L, Wu WK, Li ZJ, Li HT, Wu YC, Cho CH*. Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. Int J Cancer, 2009,125(11):2540-6

Yu L, Wu WK, Li ZJ, Liu QC, Li HT, Wu YC, Cho CH*. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol, 2009,75(6):1364-73.

Yu L, Wu WK, Li ZJ, Wong HP, Tai EK, Li HT, WU YC, Cho CH*. E series of prostaglandin receptor 2-mediated activation of extracellular signal-regulated kinase/activator protein-1 signaling is required for the mitogenic action of prostaglandin E2 in esophageal squamous-cell carcinoma. J Pharmacol Exp Ther, 2008,327(1):258-67